Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Head of Research & Development | June 07, 2021 | June 09, 2021 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Director | May 22, 2019 | May 23, 2019 |
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Director · President and CEO | April 02, 2026 | April 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date June 07, 2021 · Filed June 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,169.1121 |
Reported balance
After 2021-06-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-06-07 · Sale · Disposed 7,672 · Balance 10,169.1121 F1: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F2: Includes 102.902 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
F2: Includes 102.902 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2021.
NEUROCRINE BIOSCIENCES INC
Report date May 22, 2019 · Filed May 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.79 · Expires 2029-05-22 | Direct | 10,000 |
Reported balance
After 2019-05-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-22 · Grant · Acquired 10,000 · Balance 10,000 F1: Option vests in 12 equal monthly installments beginning June 22, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Option vests in 12 equal monthly installments beginning June 22, 2019.
Voyager Therapeutics, Inc.
Report date April 02, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 472,549 |
Reported balance
After 2026-04-02 transaction · row 1
1 source rowRow 1 · 2026-04-02 · Sale · Disposed 11,511 · Balance 472,549 F1: Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2026. The sales do not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.81 to $3.95, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2026. The sales do not represent a discretionary trade by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.81 to $3.95, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2017 Filed Jun 8, 2017 22:36 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 15,000 | $0.00 Strike: $53.64 | $0.00 |
DisclosureSEC source: 0001209191-17-038636 · doc4.xml · derivative · entry 1 Sandrock Alfred · CIK 0001577061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-22 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 22, 2017. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 20:18 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 1,981 | $274.08 | $542,952.48 |
DisclosureSEC source: 0001127602-17-013898 · form4.xml · nonDerivative · entry 1 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,059.8551 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 23:02 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 973 | $290.07 | $282,238.11 |
DisclosureSEC source: 0001127602-17-010297 · form4.xml · nonDerivative · entry 1 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,040.8551 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:22 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 815 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009826 · form4.xml · derivative · entry 20 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 815 shares Expires 2017-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F13 · shares: This award was previously reported as covering 797 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F14 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]). F13 · derivative.underlying_shares: This award was previously reported as covering 797 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F13 · balance_after: This award was previously reported as covering 797 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:22 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 628 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009826 · form4.xml · derivative · entry 19 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 628 shares Expires 2017-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F12 · shares: This award was previously reported as covering 1,336 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F7 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F12 · derivative.underlying_shares: This award was previously reported as covering 1,336 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F12 · balance_after: This award was previously reported as covering 1,336 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:22 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,569 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009826 · form4.xml · derivative · entry 18 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,828 Underlying: Common Stock · 1,569 shares Expires 2019-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F11 · shares: This award was previously reported as covering 10,006 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F6 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest each year for four years, beginning two years from the date of grant. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F11 · derivative.underlying_shares: This award was previously reported as covering 10,006 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F11 · balance_after: This award was previously reported as covering 10,006 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:22 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 398 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009826 · form4.xml · derivative · entry 17 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062 Underlying: Common Stock · 398 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F10 · shares: This award was previously reported as covering 2,074 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F7 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F10 · derivative.underlying_shares: This award was previously reported as covering 2,074 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F10 · balance_after: This award was previously reported as covering 2,074 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:22 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,375 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009826 · form4.xml · derivative · entry 16 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,960 Underlying: Common Stock · 1,375 shares Expires 2019-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. F9 · shares: This award was previously reported as covering 7,270 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F8 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). F9 · derivative.underlying_shares: This award was previously reported as covering 7,270 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F9 · balance_after: This award was previously reported as covering 7,270 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:22 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 662 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009826 · form4.xml · derivative · entry 15 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,460 Underlying: Common Stock · 662 shares Expires 2018-02-23 F5 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F7 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:22 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,103 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009826 · form4.xml · derivative · entry 14 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,335 Underlying: Common Stock · 1,103 shares Expires 2019-02-22 F5 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F8 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:22 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 738 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009826 · form4.xml · derivative · entry 13 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 628 Underlying: Common Stock · 738 shares Expires 2017-02-12 F5 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F7 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:22 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,841 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009826 · form4.xml · derivative · entry 12 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,397 Underlying: Common Stock · 1,841 shares Expires 2019-02-12 F5 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F6 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest each year for four years, beginning two years from the date of grant. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:22 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 384 | $274.76 | $105,507.84 |
DisclosureSEC source: 0001127602-17-009826 · form4.xml · nonDerivative · entry 11 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,013.8551 F4 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:22 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 815 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009826 · form4.xml · nonDerivative · entry 10 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,397.8551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:22 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 296 | $274.60 | $81,281.60 |
DisclosureSEC source: 0001127602-17-009826 · form4.xml · nonDerivative · entry 9 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,582.8551 F4 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:22 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 628 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009826 · form4.xml · nonDerivative · entry 8 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,878.8551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:22 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 739 | $274.76 | $203,047.64 |
DisclosureSEC source: 0001127602-17-009826 · form4.xml · nonDerivative · entry 7 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,250.8551 F4 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:22 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,569 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009826 · form4.xml · nonDerivative · entry 6 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,989.8551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · date: This award vested on 2/12/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:22 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 727 | $274.76 | $199,750.52 |
DisclosureSEC source: 0001127602-17-009826 · form4.xml · nonDerivative · entry 5 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,420.8551 F3 · date: On 2/12/14 an RSU was awarded for 7,740 shares vesting over 4 years. The remaining 5,805 shares were adjusted to 5,940 shares pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F3 · shares: On 2/12/14 an RSU was awarded for 7,740 shares vesting over 4 years. The remaining 5,805 shares were adjusted to 5,940 shares pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F3 · balance_after: On 2/12/14 an RSU was awarded for 7,740 shares vesting over 4 years. The remaining 5,805 shares were adjusted to 5,940 shares pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:22 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 188 | $284.75 | $53,533.00 |
DisclosureSEC source: 0001127602-17-009826 · form4.xml · nonDerivative · entry 4 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,147.8551 F2 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:22 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 398 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009826 · form4.xml · nonDerivative · entry 3 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,335.8551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: This award vested on 2/23/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:22 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 647 | $287.63 | $186,096.61 |
DisclosureSEC source: 0001127602-17-009826 · form4.xml · nonDerivative · entry 2 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,937.8551 F1 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:22 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009826 · form4.xml · nonDerivative · entry 1 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,584.8551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This award vested on 2/22/2017 and the actual number of shares that vested was determined in accordance with the terms of such award. Due to adjustments to the award to account for the Bioverativ Inc. spin-off, the number of vested shares was not determinable until 2/28/2017. Such adjusted number of vested shares was distributed to the reporting person on 2/28/2017. Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:32 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 6,380 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007117 · form4.xml · derivative · entry 1 Sandrock Alfred · CIK 0001577061 · EVP CMO Neuro & Neurodegenerat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,380 Underlying: Common Stock · 6,380 shares Expires 2020-02-15 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.